NEW YORK (GenomeWeb News) – Omicia said today that it intends to use funds from a recently closed $6.8 million Series A financing round led by Artis Ventures to expand its marketing reach and to optimize its whole-genome interpretation offering.
Other investors in the round included Acadia Woods Partners, Bay City Capital, Buchanan Investments, and Casdin Capital. As part of their investment, Tad Buchanan, principal of Buchanan Investments, and William Gerber from Bay City Capital will also join Omicia's board of directors, the company said.
Mike Aicher, Omicia's CEO, said in a statement that the investors' support would help his company rapidly execute its business plans for Opal, its software for analyzing and interpreting genomic data in research and clinical settings. Furthermore, the two new additions to the company's board "are seasoned executives and investors who will play a pivotal role in ensuring we fulfill our strategic plan," he added.